Navigation Links
Orexigen Therapeutics to Host Contrave Light Study Interim Analysis Conference Call and Webcast
Date:11/24/2013

SAN DIEGO, Nov. 24, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce results of the Light Study interim analysis on Monday, November 25, 2013 prior to market open. Following the announcement, Orexigen management will host a live webcast and conference call at 8:30 a.m. Eastern time (5:30 a.m. Pacific time).

The live call may be accessed by phone by calling (888) 895-5479 (domestic) or (847) 619-6250 (international), participant code 36202424. The webcast can be accessed live on the Investor Relations section of the Orexigen web site at www.orexigen.com and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application had been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com

McDavid Stilwell
Vice President, Corporate Communications & Business Development
858-875-8600


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
2. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
3. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
4. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
5. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
6. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
7. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
8. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
9. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
10. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
11. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held ... into an exclusive distributor agreement with ITOCHU Corporation (Tokyo ... therapy system for the treatment of cancer in ... system, is the world,s first and only MRI-guided radiation ...
(Date:1/22/2015)... 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or ... Omega-3 therapies for cardiovascular disease and overall health is pleased ... in 2014 and its outlook for 2015 from the CEO, ... We would like to take this opportunity to ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... Advocate Christ,Medical Center in Oak Lawn, Ill. has ... area, the only one in the Advocate Health Care ... a glue-like liquid for,the successful treatment of brain aneurysms ... J. Grobelny MD, of,the medical center,s Neurosciences Institute, led ...
... 19 Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) ... (NYSE: WYE ), has exercised its option ... to extend the research period for an,additional one-year ... of the,research period extension, Wyeth,s obligations to Trubion ...
Cached Medicine Technology:Advocate Christ Medical Center Using Glue-Like Liquid to Seal Off Brain Aneurysms 2Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 2Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 3
(Date:1/22/2015)... 2015 Carinsurancesavings.biz has released a new blog ... dismemberment insurance . , Purchasing an accidental death and ... advantageous. This type of rider provides benefits if the insured ... considered a lesser form of life insurance. , AD&D ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... 23, 2015 Recently, Weddingshe.com has added many ... has announced its highest annual revenues in the past three ... popular glamorous wedding dresses. , According to the sales manager ... dress promotions for them in 2015. This point can be ...
(Date:1/22/2015)... Four years since the release of their debut recording ... marriage of Avasa & Matthew Love – the duo are pleased ... release through White Swan Records on February 24, 2015. , THE ... path available to all of us to walk out of the ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the American ... effort to further promote visibility and adoption of the top ... AMA journals available via its subscription services, EBSCO will now ... , Long known as both a subscription agency and ...
Breaking Medicine News(10 mins):Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... Australian comedian has publicly apologized to sufferers of hepatitis after ... . ,Peter Helliar had cracked a joke ... ,Officials at Hepatitis Australia were annoyed at Helliar's ... the best present for Anderson on her 40th birthday. ...
... fifth-graders prefer larger portions of snacks and fast foods ... according to researchers at Dalhousie University in Canada. ... of portion sizes of french fries, meat, cooked vegetables ... usual portion sizes. , More than 63 ...
... a medical device company founded in 2004 to bring ... surgical markets, announced that vascular surgeons at the ... clinically use their novel high performance vascular sealant, ArterX(TM). ... a 74 year old man suffering from vascular insufficiency ...
... giant pharmaceutical firm is close to developing the world's first ... battle outbreaks, a news report said Friday. ,Clinical ... next year in Thailand, said Jean Stephenne, GlaxoSmithKline Biologicals president. ... the US Army for 10 years, more or less," The ...
... developed a garment with integrated electronic technology that can ... ,When placed on electronic hangers, they enable ... in the wardrobe. So theres no need to worry ... cleaned, according to Professor Bruce Thomas, Director of UniSAs ...
... that HIV/AIDS and kidney transplant patients are at higher ... than the general population. ,The study was ... Andrew Grulich at the University of New South Wales ... ,As part of the study, scientists compared ...
Cached Medicine News:Health News:Tenaxis Medical Inc. Announces First Human Use of Vascular Sealant 2Health News:An Electronic Shirt That Monitors Your Hearts Health 2
Surgical Loupes...
... is the ultimate brain machine. This ... for best image quality and fastest ... a highly compact design. ,These features ... epilepsy, tumor and multiple sclerosis. ,In ...
Signa Profile is built on the Signa foundation to deliver speed & image quality....
... Symphony II Platelet Concentrate System is a ... of Platelet Concentrate (also referred to as ... Poor Plasma (PPP) from a small sample ... the body's natural growth factors, which are ...
Medicine Products: